Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11739-020-02543-5 http://scihub22266oqcxt.onion/10.1007/s11739-020-02543-5 33165755!7649104!33165755     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Intern+Emerg+Med 2021 ; 16 (4): 957-966 Nephropedia Template TP {{tp|p=33165755|t=2021. Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry |pdf=|usr=}}{{33165755}} gab.com Text Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry JO: Intern Emerg Med http://www.kidney.de/pget.php?&tw=1&pmid=33165755 #FOAvip Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation < 92% and an elevated C reactive protein (AUC = 0.87; Hosmer-Lemeshow test, p > 0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-OR(hydroxychloroquine) 0.88; 95% CI 0.81-0.91, p = 0.005; adjusted-OR(antiviral) 0.94; 95% CI 0.87-1.01; p = 0.115). COVID-19 produces important mortality, mostly in patients with comorbidities with respiratory symptoms. Hydroxychloroquine could be associated with survival benefit, but this data need to be confirmed with further trials. Trial Registration: NCT04334291/EUPAS34399. Twit Text FOAVip Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry ????Intern Emerg Med http://www.kidney.de/pget.php?&tw=1&pmid=33165755 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33165755 #FOAvip English Wikipedia <ref>{{Cite pmid|33165755}}</ref> Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry #MMPMID33165755 Nunez-Gil IJ; Fernandez-Perez C; Estrada V; Becerra-Munoz VM; El-Battrawy I; Uribarri A; Fernandez-Rozas I; Feltes G; Viana-Llamas MC; Trabattoni D; Lopez-Pais J; Pepe M; Romero R; Castro-Mejia AF; Cerrato E; Astrua TC; D'Ascenzo F; Fabregat-Andres O; Moreu J; Guerra F; Signes-Costa J; Marin F; Buosenso D; Bardaji A; Raposeiras-Roubin S; Elola J; Molino A; Gomez-Doblas JJ; Abumayyaleh M; Aparisi A; Molina M; Guerri A; Arroyo-Espliguero R; Assanelli E; Mapelli M; Garcia-Acuna JM; Brindicci G; Manzone E; Ortega-Armas ME; Bianco M; Trung CP; Nunez MJ; Castellanos-Lluch C; Garcia-Vazquez E; Cabello-Clotet N; Jamhour-Chelh K; Tellez MJ; Fernandez-Ortiz A; Macaya C Intern Emerg Med 2021[Jun]; 16 (4): 957-966 PMID33165755show ga Recently the coronavirus disease (COVID-19) outbreak has been declared a pandemic. Despite its aggressive extension and significant morbidity and mortality, risk factors are poorly characterized outside China. We designed a registry, HOPE COVID-19 (NCT04334291), assessing data of 1021 patients discharged (dead or alive) after COVID-19, from 23 hospitals in 4 countries, between 8 February and 1 April. The primary end-point was all-cause mortality aiming to produce a mortality risk score calculator. The median age was 68 years (IQR 52-79), and 59.5% were male. Most frequent comorbidities were hypertension (46.8%) and dyslipidemia (35.8%). A relevant heart or lung disease were depicted in 20%. And renal, neurological, or oncological disease, respectively, were detected in nearly 10%. Most common symptoms were fever, cough, and dyspnea at admission. 311 patients died and 710 were discharged alive. In the death-multivariate analysis, raised as most relevant: age, hypertension, obesity, renal insufficiency, any immunosuppressive disease, 02 saturation < 92% and an elevated C reactive protein (AUC = 0.87; Hosmer-Lemeshow test, p > 0.999; bootstrap-optimist: 0.0018). We provide a simple clinical score to estimate probability of death, dividing patients in four grades (I-IV) of increasing probability. Hydroxychloroquine (79.2%) and antivirals (67.6%) were the specific drugs most commonly used. After a propensity score adjustment, the results suggested a slight improvement in mortality rates (adjusted-OR(hydroxychloroquine) 0.88; 95% CI 0.81-0.91, p = 0.005; adjusted-OR(antiviral) 0.94; 95% CI 0.87-1.01; p = 0.115). COVID-19 produces important mortality, mostly in patients with comorbidities with respiratory symptoms. Hydroxychloroquine could be associated with survival benefit, but this data need to be confirmed with further trials. Trial Registration: NCT04334291/EUPAS34399. |Aged[MESH] |COVID-19/complications/*mortality/therapy[MESH] |Female[MESH] |Hospitalization[MESH] |Humans[MESH] |Italy[MESH] |Male[MESH] |Middle Aged[MESH] |Propensity Score[MESH] |Registries[MESH] |Risk Assessment[MESH] |Risk Factors[MESH] |Spain[MESH]Mortality risk assessment in Spain and Italy, insights of the HOPE COV(epmc).pdf DeepDyve Pubget Overpricing